News
VCYT
23.56
+6.22%
1.38
Analysts’ Top Healthcare Picks: BioCryst (BCRX), Veracyte (VCYT)
TipRanks · 2h ago
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
Ark Invest sold shares of cryptocurrency-related companies on Monday. Cathie Wood-led Ark Invest reduced its stake in Robinhood Markets Inc and Coinbase Global Inc. The firm also sold a total of 35,509 shares of Bitcoin in a transaction valued at $6.9 million. On Monday, Bitcoin soared past the $56,000 mark.
Benzinga · 10h ago
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $21
Benzinga · 21h ago
Weekly Report: what happened at VCYT last week (0219-0223)?
Weekly Report · 1d ago
Veracyte’s Strategic Growth and Market Positioning Inspire Positive Analyst Outlook
Puneet Souda, an analyst from Leerink Partners, maintained the Buy rating on Veracyte (VCYT – Research Report). The associated price target is $35.00. The company has shown a solid quarter with continued growth in test volumes.
TipRanks · 1d ago
Health Care Sector Update for 02/23/2024: ARDX, VCYT, MRVI, XLV, IBB
NASDAQ · 4d ago
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
NASDAQ · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: Veracyte (VCYT), Irhythm Technologies (IRTC)
TipRanks · 4d ago
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 4d ago
Earnings Scheduled For February 22, 2024
Bausch Health Companies is expected to report quarterly earnings at $1.02 per share on revenue of $2.30 billion. Indivior is likely to report earnings for its fourth quarter. Other companies are expected to be reporting before the bell on Monday, December 11.
Benzinga · 5d ago
Veracyte Q4 2023 Earnings Preview
Seeking Alpha · 5d ago
Weekly Report: what happened at VCYT last week (0212-0216)?
Weekly Report · 02/19 10:16
Weekly Report: what happened at VCYT last week (0205-0209)?
Weekly Report · 02/12 10:10
Veracyte Streamlines Finance with Equity Sales Exemption
TipRanks · 02/07 09:13
More
Webull provides a variety of real-time VCYT stock news. You can receive the latest news about Veracyte through multiple platforms. This information may help you make smarter investment decisions.
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. It offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. It also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. It also offers customized biomarker testing and analytical services.